Anti-IL-4/-13 based therapy in Asthma

Research output: Contribution to journalLiterature reviewpeer-review

28 Citations (Scopus)


It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of IL-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were for the most part disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review is an update of the evidence demonstrating the effectiveness or otherwise of the targeting of the TH2 cytokines IL-4 and IL-13 with biologics in patients with asthma.
Original languageEnglish
Pages (from-to)349-352
Number of pages4
JournalExpert Opinion on Emerging Drugs
Issue number3
Early online date28 May 2015
Publication statusPublished - 2015


  • asthma
  • discriminatory biomarkers
  • IL-13
  • IL-4


Dive into the research topics of 'Anti-IL-4/-13 based therapy in Asthma'. Together they form a unique fingerprint.

Cite this